Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Assets Average (2016 - 2025)

Historic Assets Average for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $842.1 million.

  • Amicus Therapeutics' Assets Average rose 963.99% to $842.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $842.1 million, marking a year-over-year increase of 963.99%. This contributed to the annual value of $781.5 million for FY2024, which is 405.22% up from last year.
  • As of Q3 2025, Amicus Therapeutics' Assets Average stood at $842.1 million, which was up 963.99% from $802.6 million recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Assets Average peaked at $930.9 million during Q4 2021, and registered a low of $712.3 million during Q1 2023.
  • Moreover, its 5-year median value for Assets Average was $785.8 million (2024), whereas its average is $793.1 million.
  • Its Assets Average has fluctuated over the past 5 years, first skyrocketed by 1091.3% in 2021, then plummeted by 2030.92% in 2022.
  • Over the past 5 years, Amicus Therapeutics' Assets Average (Quarter) stood at $930.9 million in 2021, then fell by 20.31% to $741.8 million in 2022, then rose by 3.93% to $771.0 million in 2023, then rose by 1.92% to $785.8 million in 2024, then rose by 7.16% to $842.1 million in 2025.
  • Its Assets Average was $842.1 million in Q3 2025, compared to $802.6 million in Q2 2025 and $787.4 million in Q1 2025.